Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 47.8%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 30,500 shares, a decrease of 47.8% from the February 29th total of 58,400 shares. Based on an average daily volume of 271,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the shares of the company are sold short.

Institutional Investors Weigh In On Windtree Therapeutics

Several hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of Windtree Therapeutics in the fourth quarter valued at approximately $28,000. Citadel Advisors LLC bought a new position in Windtree Therapeutics in the fourth quarter worth $27,000. Vanguard Group Inc. bought a new position in Windtree Therapeutics in the third quarter worth $40,000. Envestnet Asset Management Inc. lifted its position in Windtree Therapeutics by 97.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 212,236 shares of the company’s stock worth $36,000 after purchasing an additional 104,934 shares during the period. Finally, Millennium Management LLC lifted its position in Windtree Therapeutics by 411.1% in the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after purchasing an additional 64,232 shares during the period. 29.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Windtree Therapeutics in a research report on Wednesday, January 3rd.

Windtree Therapeutics Stock Down 3.8 %

WINT opened at $0.35 on Friday. Windtree Therapeutics has a 1-year low of $0.28 and a 1-year high of $18.48. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $1.82 million, a price-to-earnings ratio of -0.02 and a beta of 0.60. The business has a 50 day moving average of $0.38 and a 200-day moving average of $0.73.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.